In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

The boss of the drugs giant behind Ozempic has quit after falling behind in the global race to develop weight-loss medication ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Novo Nordisk said Jørgensen will remain in his role temporarily to ensure a “smooth transition” while a search for his ...

Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that ...

Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...